Guardion Health Sciences, Inc. (GHSI)
NASDAQ: GHSI · IEX Real-Time Price · USD
9.11
0.00 (-0.05%)
At close: May 23, 2024, 3:31 PM
9.45
+0.34 (3.79%)
After-hours: May 23, 2024, 7:55 PM EDT

Company Description

Guardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally.

The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment.

It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com.

Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.

Guardion Health Sciences, Inc.
Guardion Health Sciences logo
Country United States
Founded 2009
IPO Date Apr 5, 2019
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 9
CEO Ms. Janet Hall

Contact Details

Address:
2925 Richmond Avenue, Suite 1200
Houston, Texas 77098
United States
Phone (800) 873-5141
Website guardionhealth.com

Stock Details

Ticker Symbol GHSI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001642375
CUSIP Number 40145Q203
ISIN Number US40145Q5009
Employer ID 47-4428421
SIC Code 2834

Key Executives

Name Position
Robert Neal Weingarten Independent Chairman and Secretary
Craig J. Sheehan Chief Commercial Officer
Janet Hall President and Chief Executive Officer
Katie Cox Chief Accounting Officer

Latest SEC Filings

Date Type Title
May 23, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 23, 2024 8-K Current Report
May 23, 2024 SCHEDULE 13G/A Filing
May 21, 2024 8-K Current Report
May 21, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 15, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 15, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
May 6, 2024 424B5 Filing
May 3, 2024 EFFECT Notice of Effectiveness